Exicure, Inc. (NASDAQ:XCUR – Get Rating) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 33,900 shares, a growth of 14.9% from the February 13th total of 29,500 shares. Based on an average daily volume of 229,200 shares, the short-interest ratio is presently 0.1 days. Approximately 11.7% of the company’s shares are short sold.
In other Exicure news, major shareholder Cbi Usa, Inc. acquired 3,400,000 shares of the firm’s stock in a transaction on Thursday, December 15th. The stock was bought at an average cost of $1.60 per share, for a total transaction of $5,440,000.00. Following the completion of the purchase, the insider now directly owns 4,218,299 shares in the company, valued at $6,749,278.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.40% of the company’s stock.
Hedge Funds Weigh In On Exicure
Hedge funds and other institutional investors have recently bought and sold shares of the stock. UBS Group AG boosted its stake in shares of Exicure by 1,766.7% during the 1st quarter. UBS Group AG now owns 186,674 shares of the company’s stock valued at $37,000 after buying an additional 176,674 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Exicure by 329.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 147,703 shares of the company’s stock valued at $29,000 after buying an additional 113,293 shares during the last quarter. Carlson Capital L P boosted its stake in shares of Exicure by 90.0% during the 3rd quarter. Carlson Capital L P now owns 190,000 shares of the company’s stock valued at $298,000 after buying an additional 90,001 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of Exicure during the 4th quarter valued at approximately $49,000. Finally, Sigma Planning Corp purchased a new position in shares of Exicure during the 3rd quarter valued at approximately $34,000. 39.00% of the stock is owned by institutional investors and hedge funds.
Exicure Price Performance
Exicure Company Profile
Exicure, Inc develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
- Get a free copy of the StockNews.com research report on Exicure (XCUR)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.